Lack of KRAS Gene Mutations in Chronic Myeloid Leukemia in Iran

  • Kooshyar, Mohammad Mahdi (Hematology Department, Cancer Molecular Pathology Research Center) ;
  • Ayatollahi, Hossein (Hematopathology Department, Cancer Molecular Pathology Research Center) ;
  • Keramati, Mohammad Reza (Hematopathology Department, Cancer Molecular Pathology Research Center) ;
  • Sadeghian, Mohammad Hadi (Hematopathology Department, Cancer Molecular Pathology Research Center) ;
  • Miri, Mohsen (Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Sheikhi, Maryam (Faculty of Medicine, Mashhad University of Medical Sciences)
  • Published : 2013.11.30


Background: The single most common proto-oncogene change in human neoplasms is a point mutation in RAS genes. A wide range of variation in frequency of KRAS mutations has been seen in hematologic malignancies. Despite this, RAS roles in leukemogenesis remain unclear. The frequency of KRAS mutations in CML has been reported to be between zero an 10%. Many attempts have been done to develop an anti-RAS drug as a therapeutic target. Materials and Methods: This cross sectional study was performed in Mashhad University of Medical Sciences, Mashhad, Iran from 2010-2012. In 78 CML patients (diagnosed according to WHO 2008 criteria) in chronic or accelerated phases, KRAS mutations in codons 12 and 13 were analyzed using a modified PCR-restriction fragment length polymorphism (RFLP) method. Results: We did not detect any KRAS mutations in this study. Conclusions: KRAS mutations are overall rare in early phase CML and might be secondary events happening late in leukemogenesis cooperating with initial genetic lesions.


Leukemia;myelogenous;chronic;BCR-ABL positive;KRAS protein;mutation


  1. Ahuja HG, Foti A, Bar-Eli M, Cline MJ (1990). The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood, 75, 1684-90.
  2. Bain BG, Clark DM, Wilkins BS (2010). Myeloprolifrative and myelodysplastic/Myeloprolifrative neoplasms and related conditions. In: Bain BG, Clark DM, Wilkins BS, editors. Bone marrrow pathology. 4th ed: Wiley-Blackwell, 240-2.
  3. Baum KJ, Ren R (2008). Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol, 1, 5.
  4. Braun BS, Shannon K (2008). Targeting Ras in myeloid leukemias. Clin Cancer Res, 14, 2249-52.
  5. Braun BS, Tuveson DA, Kong N, et al (2004). Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA, 101, 597-602.
  6. Chan IT, Kutok JL, Williams IR, et al (2004). Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest, 113, 528-38.
  7. LeMaistre A, Lee MS, Talpaz M, et al (1989). Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood, 73, 889-91.
  8. Liang DC, Shih LY, Fu JF, et al (2006). K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer, 106, 950-6.
  9. Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C (2011). Targeting the RAS signalling pathway in cancer. Bulletin Du Cancer, 98, 1019-28.
  10. McCubrey JA, Steelman LS, Abrams SL, et al (2008). Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 22, 708-22.
  11. Nagasaka T, Sasamoto H, Notohara K, et al (2004). Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol, 22, 4584-94.
  12. Needleman SW, Gutheil JC, Kapil V, Mane SM (1989). Infrequent ras activation in chronic myelogenous leukemia (CML): Activating 61st codon mutation in the CML-derived cell line, IM-9. Leukemia, 3, 827-9.
  13. Pavlu J, Andreasson C, Chuah C, et al (2007). Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. Bri J Haematol, 137, 423-8.
  14. Preston R, Dabritz J, Hanfler J, Oettle H (2010). Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leukemia Res, 34, 883-91.
  15. Sano H, Shimada A, Taki T, et al (2012). RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese childhood AML cooperative study group. Int J Hematol, 95, 509-15.
  16. Serra A, Guerrasio A, Gaidano G, et al (1993). molecular defects associated with the acute-phase CML. Leukemia Lymphoma, 11, 25-8.
  17. Steelman LS, Franklin RA, Abrams SL, et al (2011). Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia, 25, 1080-94.
  18. Stoppa G, Rumiato E, Saggioro D. (2012) Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells. Apoptosis, 17, 219-28.
  19. Stricker TP, Kumar V (2012). In: Kumar V, Abbas AK, Fausto N, Aster JC, editors (2012). Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders Elsevier, 259-320.
  20. Tyner JW, Erickson H, Deininger MW, et al (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 113, 1749-55.
  21. Watzinger F, Gaiger A, Karlic H, et al (1994). Absence of n-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid-leukemia. Cancer Res, 54, 3934-8.
  22. Zhu X, Li Y, Luo X, Fei J (2012). Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. Cellular Signalling, 24, 1134-40.

Cited by

  1. Elevated Serum Ferritin Levels in Patients with Hematologic Malignancies vol.15, pp.15, 2014,
  2. High Frequency of Codon 12 but not Codon 13 and 61 K-ras Gene Mutations in Invasive Ductal Carcinoma of Breast in a South Indian Population vol.16, pp.8, 2015,